Patent MarketPlace: Pharmaceutical Patents for Sale

Purple flowering head of an Angelica gigas Nakai plantAngelica Gigas Nakai-Based Treatments for Osteoarthritis, Vascular Diseases, and Neurodegenerative Diseases (Astrogenesis): International Patent Portfolio

Angelica gigas Nakai is a plant species historically used in traditional herbal medicine. It is primarily found in East Asia with a notable presence and long-standing use in Korea. Its deep, thick roots are traditionally harvested for their medicinal properties. For centuries, the plant has been a consistent component in various traditional remedies. The root of Angelica gigas Nakai is often decocted with water and used as a blood tonic for the treatment of gynecological diseases and as an anti-inflammatory, analgesic, and laxative. The therapeutic properties of Angelica gigas Nakai are largely attributed to its bioactive compounds, decursin and decursinol angelate. Decursin, when isolated from the root, is a primary active ingredient contributing to the plant’s biological activity.

Recent research has uncovered three additional uses for an Angelica gigas Nakai. It can be used for the prevention or treatment of osteoarthritis, the prevention or treatment of vascular disease, and the prevention or treatment of neurodegenerative diseases. Three patent families address each of these areas of treatment that all involve ethanol to produce the required level of extract. A fourth patent family of Korean and Taiwan patents addresses hair growth and the inhibition of hair loss. It includes a compound patent claiming sulforaphane and beta-sitosterol as specific chemical entities rather than plant extracts, providing broader protection that is more difficult to design around.

Patent Portfolio

This portfolio – or selected patents from the portfolio – can be used to create a line of nutraceutical remedies for conditions that affect millions in the U.S. and around the world. And because the base ingredient is organic and proven to have no serious side effects, the remedies derived from it are also safe with no side effects.

Chemical structure of an adamantane hydrazide-hydrazone compoundCompound for Management of Neurological Complications (Pawar): U.S. Patent Application 20250066288 and India Patent 532733

Adamantine and dihydrazide-dihydrazone compounds are specialized organic molecules created by linking a rigid adamantane core with active hydrazide-hydrazone functional groups. These hybrid molecules have been studied extensively in medicinal chemistry for their potent biological properties including antimicrobial, anti-tuberculosis, and anticancer activities. This patent application takes adamantane and dihydrazide-dihydrazone into totally new areas of patient treatment.

This patented compound merges the therapeutic power of the adamantane and dihydrazide-dihydrazone groups. They are already known for their efficacy in treating Type 2 diabetes, tuberculosis, and cancer. The dihydrazide-dihydrazone ability to address anti-diabetes and hypertension gives it an edge over existing treatments. Adamantane component enhances its pharmacological impact, particularly in managing neurological complications. Further, toxicity tests confirm the compound is safe, with an LD50 greater than 5000 mg/kg. The compound covered by this patent application and its efficient two-step synthesis enables scalable production, making it a strong candidate for clinical trials and commercial applications.

U.S. Patent Application 20250066288 and India Patent 532733 for a “Dihydrazide-dihydrazone compounds with adamantyl moiety and a process for synthesis of the same” can be taken into clinical trials by any pharmaceutical manufacturer with the goal of taking to market a drug to treat fungal and bacterial infections, tuberculosis, inflammatory disorders, and viral and neurodegenerative diseases.

Medication vials and syringesTest for Misuse of Opioids (Stefano): U.S. Patent No. 8,753,823

Opioid addiction is a medical crisis. But there are patients who are in pain, and an opioid-based pain killer may be the best option to relieve that pain. However, physicians who prescribe opioids need to protect themselves. Urine drug screening has been the standard that prescribing doctors use to confirm the presence of opioids in a patient’s system, but standard urine drug screening – which is mandated in all states – only shows the presence of opioids in the system and not how they got there. In many instances, patients secured opioids on their own and ingested them by snorting, liquifying, or injection. A physician needs to know the level of opioids in each patient’s system and its source to protect both the patient and the physician.

This patent covers the steps for preparing a specific antigen – in this case an opioid. The physician intravenously injects a prescription medication that includes an inert binder and was initially intended for oral consumption into the blood stream of the patient. It creates unnatural antibodies in response to antigenic stimulation. Drawing a blood sample from a patient and mixing the drawn blood sample with the prepared specific antigen determines the presence of a formation of an antibody-antigen complex indicative of medication initially intended for oral consumption intravenously injected into the blood stream of a patient.

U.S. Patent No. 8,753,823 for an “Immunoassay method for detecting the presence of antibodies to intravenously injected oral medications” can be used to develop a test that physicians can use to determine if their patients have been ingesting opioid-based drugs on their own – preventing over-dosage and reducing addiction.

Chemical structure diagram of spermine.Composition for Affecting Male and Female Hormone Levels (Nokomis Research): U.S. Patent No. 9,333,184

Hormonal imbalances – driven by aging, stress, and environmental xenoestrogens – underlie many of today's most prevalent health challenges. From estrogen dominance in both men and women to age-related fertility declines, consumers are actively searching for safe, non-synthetic, and highly effective therapeutic alternatives that address menopause, longevity, mood, stress, and heart health.

This patent introduces a clinically grounded, proprietary formulation and method utilizing precise ratios of polyamines (specifically spermine and spermidine) to naturally balance and optimize mammalian hormone levels, creating a product that supersedes those containing the singular ingredient, spermidine. This formulation has multiple benefits:

U.S. Patent No. 9,333,184 for a “Composition and method for affecting male and female hormone levels” can be used by nutraceuticals and dietary supplements suppliers to launch a premium patented hormone-support or fertility supplement line, by functional foods and wellness brands to infuse science-backed polyamines into modern wellness products, and by biotech and consumer health products suppliers to reinforce their intellectual property portfolio against competitors in the reproductive and endocrinology spaces.

Dementia patient careSmall Endogenous Molecule for Treatment of Dementia (Salama): U.S. and European Patents

Dementia is a growing global affliction. Over 40% of Americans over 65 will develop dementia. Over six million Americans currently suffer from dementia, and the disease accounts for 100,000 deaths a year. Worldwide, 57 million people suffer from dementia and 10 million new cases are reported each year.

This international patent family introduces a completely novel concept and a new mechanism of action for the oral treatment of dementia, Alzheimer's disease, and neurodegenerative disorders. It utilizes cis-4-hydroxy-L-proline (CHP) – a proline analog characterized by excellent water solubility, bioavailability, and dose linearity – that functions as a multi-target agent via a unique mechanism of action. In comprehensive pharmacological, preclinical, and clinical studies involving healthy subjects, as well as patients with solid tumors and chronic liver diseases, CHP demonstrated broad therapeutic efficacy that included antitumor, antimetastatic, and antifibrotic effects, as well as the inhibition of collagen IV and glutathione S-transferase (GST). Furthermore, in animal models and studies employing radiolabeled CHP, the compound demonstrated excellent penetration of the blood-brain barrier, as well as the potential for regeneration of cancer cell membranes. Testing has shown that in specific oral doses, cis-4-hydroxy-L-proline could be developed as an effective orally treatment for dementia!

U.S. Patent No. 10,328,051 and European Patent 3197445 for “Proline or proline derivatives for the treatment of dementia” would enable any provider of pharmaceuticals, over-the-counter medications, or dietary supplements to introduce a potentially effective prophylactic measure and biomarker for high-risk individuals, a means for the stabilization and therapy of Alzheimer's disease, and a treatment for dementia that is entirely natural and free of any side effects. The European patent is valid in Germany, the United Kingdom, and Switzerland.

Preparation of DNA Libraries (Salish): International Patent Portfolio

DNA libraries have become critical tools for the diagnosis and treatment of diseases such as cancer. DNA libraries can take on many forms. Here “DNA library” refers to DNA fragments such as circulating cell-free patient DNA (cfDNA) that are attached to specialized adapters that enable amplification of the library using Polymerase Chain Reaction. Such libraries prepared from an individual patient can be utilized to understand the genetic basis of underlying physical conditions such as cancer.

This patent portfolio addresses the need for high complexity DNA libraries from biological samples such as cfDNA. It provides novel methods and reagents specifically for targeted DNA sequencing using next-generation DNA sequencing (NGS). The intended applications include DNA sequence-based liquid biopsies. One key feature of the invention is that it improves the efficiency of cloning and the physical representation of targeted DNA fragments in NGS. Target regions are easily “programmable” using simple oligonucleotide probe sets and hybridization-based capture in optimized conditions that are described with the method. In a further embodiment, each clone is uniquely labeled. This results in NGS datasets that are amenable to quantitative analysis. The technology is ideally suited to the customized, patient-specific detection of minimal residual disease in individuals undergoing treatment for cancer.

Patent Portfolio

This portfolio – or selected patents from this portfolio – would enable any company conducting genomic research to build DNA libraries faster and at less cost.

SIRP-Based Immunotherapy (OmniAb): International Patent Portfolio

One of the most promising cancer treatments is immunotherapy. It uses substances made by the body or in a laboratory to boost the immune system, helping the body find and destroy cancer cells. Immunotherapy can treat many different types of cancer, and it can be used alone or in combination with chemotherapy and/or other cancer treatments.

Signal regulatory proteins (SIRPs) are a family of immune receptors encompassing inhibitory, activating, nonsignaling and soluble members. CD47, a broadly expressed transmembrane glycoprotein, functions as a cellular ligand for SIRPα and γ, negatively regulating phagocytosis and antibody-directed cellular cytotoxicity (ADCC). Agents that interfere with the interaction between these SIRPs and CD47 thus activate phagocytosis and ADCC. This portfolio describes SIRPγ and SIRPβ/β2 decoy polypeptides for immunotherapy treatment of cancer, anemia, transplant rejection, asthma, allergies, auto-immune disease, and viral infection. These decoy polypeptides are variants comprising at least one amino acid modification to increase affinity of the decoy polypeptide binding to CD47.

International Patent Portfolio

This portfolio will enable any provider of cancer treatments or immunotherapy drugs to introduce a new generation of polypeptide-based signal regulatory proteins.

Mini-Tablet Dispenser (Balda Medical): International Patent Portfolio

The new mini-tablets in which many drugs are being prescribed – drugs for leukemia, epilepsy, and heart disease are just three – combine the advantages of solid and liquid formulations. They are easy to swallow and provide an accurate dosage, but do not carry the risk of over- or under-dosage that liquids present.

What is needed is a dispenser specifically for this new generation of mini-tablets, and that what this international patent portfolio creates. The dispenser covered by this portfolio stores and dispenses one mini-tablet at a time without breaking or crushing tables in the process. It has an activation lock to prevent misuse. Its rotational design insures controlled dosage of the mini-tablets it holds and it provides visual control of the dosage. The unit is easily locked to secure the tablets, and it is compact enough to be easily stored in a pocketbook.

Patent Portfolio

Any manufacturer of pharmaceutical packaging could use this portfolio to introduce the first packaging product specifically designed to meet the needs of those with a prescription drug in mini-tablet form.

Opioid Medications to Prevent Overdose or Death During Treatment (Presti): International Patent Portfolio

The U.S. Department of Health and Human Services reports that deaths from drug overdose have risen steadily over the past two decades to the point that they have become the leading cause of deaths from injury in the United States. Deaths from opioid overdoses have surpassed automobile accident fatalities, the leading cause of injury deaths in U.S. for the last century. Worse yet, many opioid addicts enter treatment, but then overdose during treatment when they self-medicate with alcohol. According to the Centers for Disease Control (CDC), nearly one quarter of fatal prescription opioid overdoses in the U.S. are associated with patients making the all-too-common mistake of drinking alcohol while medicated. When combined, alcohol and opioids interact in the brain increasing the risk of respiratory depression and death.

This portfolio aims to prevent opioid deaths head-on by solving this critical, but previously unaddressed, dimension of the opioid crisis. It includes several combination drug therapies that reduce the likelihood of an alcohol-mediated opioid overdose or death during maintenance therapy for management of pain or opioid use disorder. It covers a single composition comprising an effective amount of one or more opioid medications and an effective amount of one of 20 aldehyde dehydrogenase inhibitors or one of 65 opioid medications. It also includes a combination medication comprised of an effective amount of one or more opioid medications, an effective amount of one or more aldehyde dehydrogenase inhibitors, and a pharmaceutical carrier.

This extensive portfolio additionally includes a combination medication that is comprised of one or more opioid medications from 1 to 200 mg, a disulfiram or pharmaceutically acceptable salt from 50 to 250 mg, and a carrier. Specifically directed at reducing an alcohol-mediated opioid overdose or death during maintenance therapy for pain management, the portfolio covers a single composition comprised of one or more opioid pain medications from 1 to 200 mg and a disulfiram or pharmaceutically acceptable salt from 50 to 250 mg that prevents alcohol consumption in the patient. There are additional formulations in three pending patent applications.

Patent Portfolio

This portfolio offers a pharmaceutical company the opportunity to introduce the next generation of opioid treatments – a regimen that specifically addresses opioid patients that face severe pains issues during treatment at high risk of drinking alcohol during their treatment for pain or addiction.

Nutraceutical Treatment for Gout (Truscott): U.S. and European Patents

Gout is a form of inflammatory arthritis that is caused by excess uric acid in the blood that crystallizes in joints and other tissues. Among those with gout, 90% have kidneys that don’t adequately remove uric acid from their urine, while 10% have high uric acid levels because their bodies produce too much uric acid. Between eight and nine million Americans suffer from gout – and millions more in Europe. Gout can be very painful – even disabling. Most treatments for gout address the pain and inflammation caused by the condition, not the root cause of the disease!

This portfolio covers a safe and effective treatment for gout that is composed of natural ingredients – celery seed extract, cherry extract, and elemental lithium in a lithium salt. The components work synergistically to inhibit painful uric acid crystals by three different modes of action: Inhibition of uric acid formation (celery seed extract), increase in uric acid elimination from the body (cherry extract), and interference with crystallization itself (lithium). Since the ingredients are all-natural, a gout treatment based on these patents can be sold over-the-counter without a prescription.

U.S. Patent No. 9,149,500 and European Patent 2303302 for a “Method and process for relieving or preventing symptoms” would enable any pharmaceutical supplier or natural remedy manufacturer to bring a treatment for gout to the market very quickly!

Urinary Tract Infection Prevention and Treatment (Biomedicals Science Sweden): International Patent Portfolio

In the science fiction thriller The Andromeda Strain, scientists attempting to stop an infection from outer space discover that the disease can only survive in a narrow pH range. The same is true of many infections here on earth including bacteria that can make its way up the urinary tract to infect the bladder (causing cystitis) or kidneys (causing pyelonephritis). Controlling the pH level in the patient’s urinary tract can prevent bacteria from becoming an infection.

This portfolio covers alternating administrations of a pH-increasing agent with the administration of a pH-decreasing agent to the patient via a mannose solution. The pH-increasing agent is administered at a dosage of about 0.1 to 20 grams per day, while the pH-decreasing agent is administered to at a dosage of about 0.1 to 20 grams per day, and the mannose or other solution is administered to at a dosage of about 0.1 to 50 grams per day.

Urinary Tract Infection Portfolio

This portfolio can be developed into a product that is sold over-the-counter in pharmacies or is used in physician’s offices as a pre-treatment prior to prescribing antibiotics. It can also be used in hospitals after surgery to lower the risk of infection and as a product for catheter patients, significantly lowering the use of antibiotics among this high-risk infection group. This portfolio will enable any drug manufacturer to introduce a product that totally prevents, or very quickly and effectively treats, a urinary tract infection without the use of antibiotics and their resulting side effects.

Treatment for Afflictions of the Central Nervous System (Numazawa): U.S. and Japanese Patents

It is not uncommon for a drug that was originally developed to treat one disease or condition to be found to also treat another disease or condition. For example, minoxidil, the active ingredient in Rogaine® (the popular treatment for male pattern baldness) was originally developed to treat high blood pressure! This is known as “drug repositioning.”

This patent portfolio addresses new uses for two existing drugs – Methocarbamol and Chlorphenesin Carbamate – for the treatment of central nervous system afflictions such as mood disorders, mental disorders, chronic fatigue syndrome, depression, and Alzheimer’s. The inventor has three published medical research papers documenting the effectiveness of this patented drug combination.

This portfolio includes U.S. Patent No. 11,364,218 for a “Method of treating or preventing mood disorders, mental disorders, and/or chronic fatigue syndrome” and Japanese Patent 6216913 for a “Pharmaceutical composition.” Since the two drugs on which the patents are based are already FDA-approved, the acquirer of the patents should be able to go to market with a drug for the treatment of depression and Alzheimer’s fairly quickly.

Rogaine is a registered trademark of Johnson & Johnson Services, Inc.

Production of Very Pure HMR and NTG Lignans (Montisera): International Patent Portfolio

Lignans are a little-known group of low molecular weight polyphenols that are derived from trees and other ligneous plants. HMR (hydroxymatairesinol) lignans are a powerful antioxidant and immune system booster that is used in by humans as well as dogs and cats. It is also an enterolactone precursor with anticancer activities. Testing has shown that HMR lignans decrease the volume of induced tumors and stabilize established tumors – and prevent the development of new tumors – in rats. HMR lignans and NTG (nortrachelogenin) lignans are also key ingredients in natural cosmetics that offer anti-aging properties. Research has shown promise for NTG lignans in treating prostate cancer.

The challenge is refining lignans through the fractionation of knotwood extract. This portfolio covers a process that in which hydrophilic extract is extracted with a lipophilic solvent that removes lipophilic impurities. The portfolio also covers the use of liquid-to-liquid extraction for the purification of hydrophilic knotwood extract. The patented process provides a purified extract that contains more than 90 % lignans, flavonoids, and stilbenes, and less than 10 % in impurities.

Patent Portfolio